A novel small molecule in the Terpenoid Therapeutics Inc. (TTI) pipeline reduces metastases in a mouse model of prostate cancer. The results are published as a manuscript titled “Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis,” which recently appeared in the journal Clinical & Experimental Metastasis. Dr. Ray Hohl, Director of the Penn State Cancer Institute is the senior author. The data shows a 54% reduction in total adrenal tumor burden as compared to untreated controls. The innovative TTI compound affects an important signaling pathway which serves as a biomarker in these experiments.
- Terpenoid Therapeutics Inc. molecule is effective against pulmonary fibrosis in a mouse model
- Terpenoid Therapeutics Inc. molecule is effective prostate cancer metastasis in a mouse model
- Start-ups get feedback at Innovation Expo
- Recasting natural product research
- Terpenoid Therapeutics a Prometheus Award Finalist for the second time